ALDEYRA THERAPEUTICS, INC. Operating Cash Flow
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Operating Cash Flow of -$9.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$4.59M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$5.11M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.30M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$7.02M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$33.35M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$43.21M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$30.33M.
- ALDEYRA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$56.64M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$9.70M 10-Q · filed 2026-08-06 | -$15.00M derived: sum of 3 quarters · filed 2026-08-06 | -$22.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$5.11M 10-Q · filed 2026-05-07 | -$10.41M derived: sum of 2 quarters · filed 2026-05-07 | -$17.43M derived: sum of 3 quarters · filed 2026-05-07 | -$25.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$12.32M derived: sum of 2 quarters · filed 2026-02-27 | -$20.88M derived: sum of 3 quarters · filed 2026-08-06 | -$33.35M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$7.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$15.58M derived: sum of 2 quarters · filed 2026-08-06 | -$28.05M 10-Q · filed 2025-11-05 | -$40.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$8.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$21.02M 10-Q · filed 2026-08-06 | -$33.06M derived: sum of 3 quarters · filed 2026-08-06 | -$41.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$12.47M 10-Q · filed 2026-05-07 | -$24.51M derived: sum of 2 quarters · filed 2026-05-07 | -$32.48M derived: sum of 3 quarters · filed 2026-05-07 | -$45.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$12.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$20.01M derived: sum of 2 quarters · filed 2026-02-27 | -$33.24M derived: sum of 3 quarters · filed 2026-02-27 | -$43.21M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$7.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$21.20M derived: sum of 2 quarters · filed 2025-11-05 | -$31.17M 10-Q · filed 2025-11-05 | -$30.67M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$13.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$23.20M 10-Q · filed 2025-08-07 | -$22.70M derived: sum of 3 quarters · filed 2025-08-07 | -$30.72M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$9.97M 10-Q · filed 2025-05-14 | -$9.47M derived: sum of 2 quarters · filed 2025-05-14 | -$17.50M derived: sum of 3 quarters · filed 2025-05-14 | -$30.85M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $500.44K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$7.52M derived: sum of 2 quarters · filed 2025-02-28 | -$20.88M derived: sum of 3 quarters · filed 2025-02-28 | -$30.33M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$8.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$21.38M derived: sum of 2 quarters · filed 2024-11-07 | -$30.83M 10-Q · filed 2024-11-07 | -$42.06M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$13.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$22.80M 10-Q · filed 2024-08-01 | -$34.03M derived: sum of 3 quarters · filed 2024-08-01 | -$46.61M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$9.44M 10-Q · filed 2024-05-02 | -$20.67M derived: sum of 2 quarters · filed 2024-05-02 | -$33.25M derived: sum of 3 quarters · filed 2024-05-02 | -$53.21M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$11.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$23.81M derived: sum of 2 quarters · filed 2024-03-07 | -$43.76M derived: sum of 3 quarters · filed 2024-03-07 | -$56.64M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$12.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$32.53M derived: sum of 2 quarters · filed 2023-11-03 | -$45.41M 10-Q · filed 2023-11-03 | -$56.98M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | -$19.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$32.83M 10-Q · filed 2023-08-03 | -$44.41M derived: sum of 3 quarters · filed 2023-08-03 | -$52.84M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$12.87M 10-Q · filed 2023-05-04 | -$24.45M derived: sum of 2 quarters · filed 2023-05-04 | -$32.88M derived: sum of 3 quarters · filed 2023-05-04 | -$41.96M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$11.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$20.01M derived: sum of 2 quarters · filed 2023-03-09 | -$29.08M derived: sum of 3 quarters · filed 2023-03-09 | -$42.56M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$8.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$17.51M derived: sum of 2 quarters · filed 2022-11-10 | -$30.98M 10-Q · filed 2022-11-10 | -$39.30M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$9.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$22.54M 10-Q · filed 2022-08-05 | -$30.86M derived: sum of 3 quarters · filed 2022-08-05 | -$37.10M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | -$13.47M 10-Q · filed 2022-05-05 | -$21.79M derived: sum of 2 quarters · filed 2022-05-05 | -$28.03M derived: sum of 3 quarters · filed 2022-05-05 | -$35.61M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$8.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$14.55M derived: sum of 2 quarters · filed 2022-03-17 | -$22.13M derived: sum of 3 quarters · filed 2022-03-17 | -$37.49M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$6.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | -$13.82M derived: sum of 2 quarters · filed 2021-10-28 | -$29.18M 10-Q · filed 2021-10-28 | -$40.40M derived: sum of 4 quarters · filed 2021-10-28 |
| 2020-06-30 | -$7.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$22.94M 10-Q · filed 2021-08-05 | -$34.17M derived: sum of 3 quarters · filed 2021-08-05 | -$42.48M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$15.36M 10-Q · filed 2021-05-06 | -$26.59M derived: sum of 2 quarters · filed 2021-05-06 | -$34.90M derived: sum of 3 quarters · filed 2021-05-06 | -$47.71M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$11.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$19.54M derived: sum of 2 quarters · filed 2021-03-11 | -$32.35M derived: sum of 3 quarters · filed 2021-03-11 | -$44.98M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$8.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$21.13M derived: sum of 2 quarters · filed 2020-11-05 | -$33.76M 10-Q · filed 2020-11-05 | -$41.73M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | -$12.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$25.44M 10-Q · filed 2020-08-06 | -$33.41M derived: sum of 3 quarters · filed 2020-08-06 | -$41.10M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | -$12.63M 10-Q · filed 2020-05-07 | -$20.60M derived: sum of 2 quarters · filed 2020-05-07 | -$28.29M derived: sum of 3 quarters · filed 2020-05-07 | -$34.53M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$7.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$15.66M derived: sum of 2 quarters · filed 2020-03-12 | -$21.90M derived: sum of 3 quarters · filed 2020-03-12 | -$29.86M 10-K · filed 2020-03-12 |
| 2018-09-30 | -$7.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$13.93M derived: sum of 2 quarters · filed 2019-11-07 | -$21.89M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | -$6.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$14.20M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | -$7.95M 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | -$19.22M 10-K · filed 2019-03-08 | |||
| 2017-09-30 | -$4.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$14.20M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | -$9.50M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |